Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single Dose Study to Assess Intrapulmonary Pharmacokinetics of ME1100 Inhalation Solution Administered to Healthy Volunteers

Trial Profile

An Open-label, Single Dose Study to Assess Intrapulmonary Pharmacokinetics of ME1100 Inhalation Solution Administered to Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arbekacin (Primary)
  • Indications Nosocomial pneumonia
  • Focus Pharmacokinetics
  • Sponsors Meiji Seika Pharma
  • Most Recent Events

    • 10 Jun 2019 Population pharmacokinetic results from ME1100-CL-102, ME1100-CL-103 and post-marketing study were published in the Antimicrobial Agents and Chemotherapy.
    • 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
    • 09 Sep 2014 Results of a pooled analysis of this trial and a single ascending dose trial were presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top